Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 27 of 43

26 OctOber 2026 Inhalation e delivery of phages into the lungs via aerosoliza- tion can be achieved either as liquid aerosols or dry powders (solid). Nebulizers are used to generate fine liquid aerosols and can operate using compressed air (jet nebulizers), ultrasonic waves (ultrasonic neb- ulizers) or vibrations (vibrating mesh nebulizers). During droplet formation using these nebulizers, phages are prone to shear stress and thermal stress (in the case of ultrasonic nebulizers) [17]. erefore, nebulization can negatively impact phage viability and reduce the phage titer delivered into the lungs. In general, the dry solid form is preferred over the aqueous state, owing to its superior stability. Drying techniques such as spray drying, spray-freeze drying and lyophilization are being investigated to prepare more stable phage-based dry powder inhalers (DPIs) [18]. However, the mechanical and thermal stresses encountered during drying may be unfavorable to phage viability. Protective excipients have been uti- lized to protect phages during manufacturing and prevent viability loss during aerosolization (discussed later in this article). e use of these excipients can also reduce direct exposure to stressors, as opposed to liquid formulations [19]. Once phages are aerosolized, effective deposition in the lungs is a major determinant of the efficacy of inhaled phage delivery. Lung deposition of phages is determined by the aerodynamic behavior of the par- ticles, particle size, particle density, flow properties and the device used for aerosolization [19]. Some phages may become inactivated after aerosolization and before deposition on the surface of the lung air- ways, resulting in fewer phages than expected reach- ing the infection site. Phages can interact with several components after deposition in the lung airways Phages are very specific to their bacterial host and have precise target specificity. Unlike antibiotics, the lytic cycle enables phages to continue self- amplification in the presence of the bacterial host. Called in situ replication, this process enables auto-dosing without repeated administration [12]. Phages encode enzyme depolymerases, which can breakdown the polysaccha- rides of biofilms (large bacterial aggregates that are common in chronic infections). Phages can mutate along with their host bacteria and this co-evolution prevents or delays the onset of phage resistance [13]. Challenges in inhaled phage delivery e highly specific nature of phage activity necessi- tates the identification of the causative bacteria and propagation of its complementary phage. For ther- apeutic purposes, high phage titers (10 10 PFU/mL) need to be produced, which requires optimization of phage propagation in the presence of bacteria at various multiplicities of infection (phage/bacteria ratio), ranging from 10 2 -10 5 [14]. During propaga- tion, harmful components released during replica- tion, such as endotoxins, host cell protein and media components, can be pyrogenic in nature. e removal of these contaminants during downstream processing by methods such as filtration, ultracentrifugation or extraction with an immiscible solvent is vital to ensure the safety of phage-based therapeutics [15]. Phages are inherently sensitive to physical and chemical stresses such as temperature, pH, interfacial adsorption and shear. ese stressors can impact the structural integ- rity of phages and may lead to loss of phage viability. Furthermore, exposure to these stresses during man- ufacturing, storage and delivery is unavoidable [16]. Figure 2 Physiological barriers to the inhaled delivery of phages Aerosolization losses Nebulizer Dry powder inhaler Deposition depends on particle size ≥ 5 µm 1-5 µm < 1 µm exhaled Mucociliary clearance Bacteria Airway mucus Respiratory epithelium Tight junctions Alveolar airspace Macrophage uptake Surfactant Systemic circulation Alveolar air-blood barrier Capillary (blood)

Articles in this issue

view archives of Inhalation - INH1026